Evolva updates financial guidance

Reinach, Switzerland, 18 February 2013 – Evolva Holding SA (SIX: EVE) today updated its financial guidance of November 2012. Based on preliminary, unaudited accounts, revenues were approximately CHF 7 million in 2012 (2011: CHF 11.1 million) and the cash position at year-end 2012 amounted to approximately CHF 10 million (of which 1 million was restricted), in line with the guidance in November 2012. The financial report for 2012 will be published on 9 April 2013.

For 2013, Evolva maintains its expectation of a significant increase in revenues from the level achieved in 2012, and now guides that these are expected to be in the CHF 10-13 million range.

Evolva also announces that Norbert Bender, Chief Medical Officer, will be taking up a position at another company with effect from 1 June 2013. Dr. Bender joined Evolva in May 2011 after working as a medical consultant to the company since October 2010.

Neil Goldsmith, Chief Executive Officer of Evolva, said: “We would like to thank Norbert for his contribution to Evolva to date, and wish him well in his new position. In line with its strategy of focusing on ingredients for health, wellness and nutrition, the Company does not currently contemplate hiring a replacement.”

– Ends –

Download press release in English
Download press release in German

About Evolva

Evolva’s mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create and optimise small molecule compounds and their production routes. We are active in consumer healthcare and nutrition as well as in pharma. In both areas we have partnered projects as well as proprietary programmes. For more information see www.evolva.com.


Contact Details

Neil Goldsmith, CEO Jakob Dynnes Hansen, CFO Paul Verbraeken, IR
neilg@evolva.com jakobdh@evolva.com paulv@evolva.com
+ 41 61 485 2005 + 41 61 485 2034 + 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.